Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention

Matteo Nicola Dario Di Minno, Anna Guida, Marina Camera, Susanna Colli, Giovanni Di Minno, Elena Tremoli

Research output: Contribution to journalArticle

Abstract

Platelets play a central role in the pathophysiology of atherothrombosis, an inappropriate platelet activation leading to acute ischemic complications (acute myocardial infarction, ischemic stroke). In view of this, platelets are a major target for pharmacotherapy. Presently, the main classes of antiplatelet agents approved for the use in such complications are aspirin and thienopyridines. Although antiplatelet treatment with these two types of drugs, alone or in combination, leads to a significant reduction of non-fatal myocardial infarction (-32%), non-fatal stroke (-25%), and of cardiovascular death (-17%), a residual risk persists. Newer antiplatelet agents have addressed some, but not all, these limitations. Vis - vis their net clinical benefit, the higher potency of some of them is associated with a rise in bleeding complications. Moreover, newer thienopyridines do not show advantages over and above the older ones as to reduction of stroke. A concerted effort that takes into consideration clinical, genetic, and laboratory information is increasingly recognized as a major direction to be pursued in the area. The well-established road signs of clinical epidemiology will provide major information to define newer potentially useful targets for platelet pharmacology.

Original languageEnglish
Pages (from-to)531-544
Number of pages14
JournalAnnals of Medicine
Volume43
Issue number7
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Platelet Aggregation Inhibitors
Thienopyridines
Blood Platelets
Myocardial Infarction
Stroke
Platelet Activation
Aspirin
Epidemiology
Pharmacology
Hemorrhage
Drug Therapy
Pharmaceutical Preparations
Therapeutics

Keywords

  • Aspirin failure
  • Cardiovascular prevention
  • Clopidogrel failure
  • New antiplatelet drugs

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Overcoming limitations of current antiplatelet drugs : A concerted effort for more profitable strategies of intervention. / Minno, Matteo Nicola Dario Di; Guida, Anna; Camera, Marina; Colli, Susanna; Minno, Giovanni Di; Tremoli, Elena.

In: Annals of Medicine, Vol. 43, No. 7, 11.2011, p. 531-544.

Research output: Contribution to journalArticle

Minno, Matteo Nicola Dario Di ; Guida, Anna ; Camera, Marina ; Colli, Susanna ; Minno, Giovanni Di ; Tremoli, Elena. / Overcoming limitations of current antiplatelet drugs : A concerted effort for more profitable strategies of intervention. In: Annals of Medicine. 2011 ; Vol. 43, No. 7. pp. 531-544.
@article{88de086cc63943b88473d5bd208f477d,
title = "Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention",
abstract = "Platelets play a central role in the pathophysiology of atherothrombosis, an inappropriate platelet activation leading to acute ischemic complications (acute myocardial infarction, ischemic stroke). In view of this, platelets are a major target for pharmacotherapy. Presently, the main classes of antiplatelet agents approved for the use in such complications are aspirin and thienopyridines. Although antiplatelet treatment with these two types of drugs, alone or in combination, leads to a significant reduction of non-fatal myocardial infarction (-32{\%}), non-fatal stroke (-25{\%}), and of cardiovascular death (-17{\%}), a residual risk persists. Newer antiplatelet agents have addressed some, but not all, these limitations. Vis - vis their net clinical benefit, the higher potency of some of them is associated with a rise in bleeding complications. Moreover, newer thienopyridines do not show advantages over and above the older ones as to reduction of stroke. A concerted effort that takes into consideration clinical, genetic, and laboratory information is increasingly recognized as a major direction to be pursued in the area. The well-established road signs of clinical epidemiology will provide major information to define newer potentially useful targets for platelet pharmacology.",
keywords = "Aspirin failure, Cardiovascular prevention, Clopidogrel failure, New antiplatelet drugs",
author = "Minno, {Matteo Nicola Dario Di} and Anna Guida and Marina Camera and Susanna Colli and Minno, {Giovanni Di} and Elena Tremoli",
year = "2011",
month = "11",
doi = "10.3109/07853890.2011.582137",
language = "English",
volume = "43",
pages = "531--544",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Overcoming limitations of current antiplatelet drugs

T2 - A concerted effort for more profitable strategies of intervention

AU - Minno, Matteo Nicola Dario Di

AU - Guida, Anna

AU - Camera, Marina

AU - Colli, Susanna

AU - Minno, Giovanni Di

AU - Tremoli, Elena

PY - 2011/11

Y1 - 2011/11

N2 - Platelets play a central role in the pathophysiology of atherothrombosis, an inappropriate platelet activation leading to acute ischemic complications (acute myocardial infarction, ischemic stroke). In view of this, platelets are a major target for pharmacotherapy. Presently, the main classes of antiplatelet agents approved for the use in such complications are aspirin and thienopyridines. Although antiplatelet treatment with these two types of drugs, alone or in combination, leads to a significant reduction of non-fatal myocardial infarction (-32%), non-fatal stroke (-25%), and of cardiovascular death (-17%), a residual risk persists. Newer antiplatelet agents have addressed some, but not all, these limitations. Vis - vis their net clinical benefit, the higher potency of some of them is associated with a rise in bleeding complications. Moreover, newer thienopyridines do not show advantages over and above the older ones as to reduction of stroke. A concerted effort that takes into consideration clinical, genetic, and laboratory information is increasingly recognized as a major direction to be pursued in the area. The well-established road signs of clinical epidemiology will provide major information to define newer potentially useful targets for platelet pharmacology.

AB - Platelets play a central role in the pathophysiology of atherothrombosis, an inappropriate platelet activation leading to acute ischemic complications (acute myocardial infarction, ischemic stroke). In view of this, platelets are a major target for pharmacotherapy. Presently, the main classes of antiplatelet agents approved for the use in such complications are aspirin and thienopyridines. Although antiplatelet treatment with these two types of drugs, alone or in combination, leads to a significant reduction of non-fatal myocardial infarction (-32%), non-fatal stroke (-25%), and of cardiovascular death (-17%), a residual risk persists. Newer antiplatelet agents have addressed some, but not all, these limitations. Vis - vis their net clinical benefit, the higher potency of some of them is associated with a rise in bleeding complications. Moreover, newer thienopyridines do not show advantages over and above the older ones as to reduction of stroke. A concerted effort that takes into consideration clinical, genetic, and laboratory information is increasingly recognized as a major direction to be pursued in the area. The well-established road signs of clinical epidemiology will provide major information to define newer potentially useful targets for platelet pharmacology.

KW - Aspirin failure

KW - Cardiovascular prevention

KW - Clopidogrel failure

KW - New antiplatelet drugs

UR - http://www.scopus.com/inward/record.url?scp=80053091829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053091829&partnerID=8YFLogxK

U2 - 10.3109/07853890.2011.582137

DO - 10.3109/07853890.2011.582137

M3 - Article

C2 - 21815879

AN - SCOPUS:80053091829

VL - 43

SP - 531

EP - 544

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 7

ER -